Hydroxyurea therapy associated with declining serum levels of magnesium in children with sickle cell anemia

Objective: To obtain quantitative serum levels of total and ionized magnesium (Mg2+) children with homozygous sickle cell anemia (SCA) undergoing therapy with hydroxyurea. Study design: Five children, ages 11 to 14 years with homozygous SCA, were enrolled in a dose-escalating trial of hydroxyurea over an 18-month period. Serum levels of total and ionize magnesium together with ionized K+, Na+, and Ca2+, were measured before hydroxyurea and every 6 months during hydroxyurea therapy. Results: Before treatment, 4 of the 5 patients had low or below-normal serum concentrations of Mg2+, (normal range, 0.51-0.67 mmol/L). All 5 became Mg2+-deficient during hydroxyurea therapy, with no indication of recovery until after 12 to 18 months of drug administration (P <.05). Similar changes were noted for total magnesium concentrations. Mean serum levels of K+, Na+, and Ca2+, remained consistently within normal ranges. Conclusions: These Findings warrant a controlled study of the effects of magnesium supplementation in patients with SCA receiving hydroxyurea. Potentially, such therapy could alleviate or prevent vaso-occlusive crises.